BPG is committed to discovery and dissemination of knowledge
Articles in Press
1/23/2023 6:04:52 PM | Browse: 71 | Download: 181
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 81119
Country/Territory Türkiye
Category Oncology
Manuscript Type Retrospective Cohort Study
Article Title Prognostic value of Claudin 18.2 expression in gastric adenocarcinoma
Manuscript Source Unsolicited Manuscript
All Author List Erkan Kayikcioglu, Ramazan Oğuz Yüceer, Bulent Cetin, Kamuran Yüceer and Nermin Karahan
Funding Agency and Grant Number
Corresponding Author Erkan Kayikcioglu, MD, Assistant Professor, Department of Medical Oncology, Suleyman Demirel University, Cunur, Suleyman Demirel Caddesi, Isparta 32260, Türkiye. drkayikcioglu@yahoo.com
Key Words Gastric adenocarcinoma; Claudin 18.2; Overall survival; Clinicopathological characteristics
Core Tip Zolbetuximab is a new antibody drug targeting the cell surface protein claudin 18.2 (CLDN 18.2) expressed by gastric cancer cells. CLDN 18.2 expression, identifying the patient population who are susceptible to zolbetuximab, is discordant in different studies. The present study aimed to research the expression ratio of CLDN and its prognostic value for overall survival in patients with gastric adenocarcinoma in a single center located in Turkey.
Citation Kayikcioglu E, Yüceer RO, Cetin B, Yüceer K, Karahan N. Prognostic value of Claudin 18.2 expression in gastric adenocarcinoma. World J Gastrointest Oncol 2023; 15(2): 343-351
Received
2022-10-29 10:58
Peer-Review Started
2022-10-29 11:01
To Make the First Decision
Return for Revision
2022-12-30 05:22
Revised
2023-01-02 14:44
Second Decision
2023-01-20 03:30
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2023-01-23 18:04
Articles in Press
2023-01-23 18:04
Publication Fee Transferred
Edit the Manuscript by Language Editor
2023-01-29 17:21
Typeset the Manuscript
2023-02-07 06:43
ISSN 1948-5204 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com